Wockhardt Seeks DCGI Approval for Fast-Acting Insulin Analog Aspart Injection
Key Insights
Wockhardt has filed for approval of its fast-acting insulin analog, Aspart injection (search) (ASPARAPIDTM), with the Drugs Controller General of India (DCGI) in India.
The Aspart insulin injection aims to help patients effectively manage their diabetes (search), offering a new treatment option in the growing Indian market.
The Indian market for Aspart insulin is currently estimated at over Rs 260 crore, with Wockhardt anticipating significant growth in the coming years.
Wockhardt has announced the filing of its fast-acting insulin analog, Aspart injection (search) (ASPARAPIDTM), with the Drugs Controller General of India (DCGI) for marketing approval. This move signifies Wockhardt's commitment to addressing the increasing prevalence of diabetes (search) in India and globally. If approved, Aspart will be available in cartridges, vials, and prefilled disposable pens.
Market and Competition
The current market size for Aspart in India is estimated to be over Rs 260 crore, with only two other players currently offering similar products. Wockhardt anticipates substantial market growth in the coming years, driven by the increasing need for effective diabetes (search) management solutions.
Wockhardt's Diabetes Portfolio Expansion
In addition to Aspart, Wockhardt is actively developing other insulin analogs and GLP-1 agonists (search). The company aims to create a comprehensive diabetes (search) portfolio, providing patients with a wider range of advanced treatment options for managing their condition. This filing underscores Wockhardt's end-to-end capabilities in research & development, clinical studies, scale-up, and manufacturing of biosimilar products.
Wockhardt's Recent Regulatory Success
Recently, Wockhardt received a favorable recommendation from the Central Drugs Standard Control Organisation (CDSCO) for its antibiotic drug Miqnaf, used in treating community-acquired bacterial pneumonia (search) (CABP) among adults.